Compare Moderna, Inc. (MRNA) vs Unity Software Inc (U) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Unity Software Inc — how do they compare? Moderna, Inc. trades at $195.61 (market cap $78.65B), while Unity Software Inc trades at $46.34 (market cap $20.00B). The key difference: Moderna, Inc. is far larger — about 3.9× Unity Software Inc's market cap, and Moderna, Inc. is more actively traded (37,373,437 versus 12,798,386). Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Unity Software Inc for 50 Days on average.
| MRNA | U | |
|---|---|---|
Market Cap | $78.65B | $20.00B |
Volume | 37,373,437 | 12,798,386 |
Sector | Health | Technology |
52-Week High | $203.46 | $49.47 |
52-Week Low | $22.36 | $17.13 |
Typical Hold Time | 59 Days | 50 Days |
Enterprise Value | $74.80B | $19.88B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $196.48, up 4.81% amid Nasdaq-100 inclusion news, though it remains well below the analyst consensus target of $115.70. The stock shows bullish technical momentum with recent earnings beats, but faces fundamental challenges with negative profit margins and declining revenue from pandemic-era highs. The company's cash flow improved in 2025, turning positive for the first time since 2022, while its pipeline, including oncology vaccines, attracts investor interest despite valuation concerns.
Outlook: Near-term momentum from index fund buying and pipeline updates may support the stock, but high valuation multiples and persistent losses pose significant risks. Long-term growth depends on successful commercialization of non-COVID products, with current prices reflecting optimistic scenarios. Investors should weigh the potential of the mRNA platform against execution risks and competitive pressures.
Unity Software (U) trades at $45.44, up 1.09% with bullish technical momentum and strong analyst support. The stock shows improving fundamentals with revenue stabilizing around $1.8B and narrowing losses, though profitability remains negative. Recent news highlights Meta VR partnership driving investor optimism, with technical indicators showing the stock testing resistance near $46.
Unity presents a growth story with improving cash flow and strategic partnerships, but faces execution risks amid persistent losses. With 82% analyst buy ratings and a $46.54 price target, Wall Street sees upside potential, though investors must weigh high valuation multiples against the company's path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Unity Software Inc
Unity Software Inc provides a software platform for creating and operating interactive, real-time 3D content. The platform can be used to create, run and monetize interactive, real-time 2D and 3D content for mobile phones, tablets, PCs, consoles, and augmented and virtual reality devices. The business is spread across the United States, Greater China, EMEA, APAC and Other Americas, of which key revenue is derived from the EMEA region. The products are used in the gaming industry, architecture and construction sector, animation industry, and designing sector.
Read more on U →
